Search company, investor...
Search

Predict your next investment

AbbVie company logo
Corporation
HEALTHCARE | Biotechnology
abbvie.com

See what CB Insights has to offer

Investments

3

Portfolio Exits

1

Partners & Customers

10

Service Providers

1

About AbbVie

AbbVie (NYSE: ABBV) consists of scientists, researchers, communicators, manufacturing specialists, and regulatory professionals who seek to come up with new approaches to addressing today's health issues-from life-threatening illness to chronic conditions. The company focuses its R&D efforts and technology investments to pursue this goal.

AbbVie Headquarters Location

1 Waukegan Road

North Chicago, Illinois, 60064,

United States

800-255-5162

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AbbVie

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find AbbVie in 4 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

D

Diabetes

1,750 items

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

B

Biopharma Tech

260 items

AbbVie Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AbbVie Rank

Research containing AbbVie

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned AbbVie in 2 CB Insights research briefs, most recently on Aug 3, 2021.

Latest AbbVie News

TiumBio gets $4.5 million upfront from China’s Hansoh Pharmaceutical

Sep 29, 2022

TiumBio gets $4.5 million upfront from China’s Hansoh Pharmaceutical 바로가기 기자명 Kim Chan-hyuk 닫기 TiumBio said on Tuesday that it received a $4.5 million upfront payment from China’s Hansoh Pharmaceutical under the previous licensing agreement involving TU2670, a new endometriosis treatment. Earlier in August, TiumBio and Hansoh signed a $170 million deal, including a $4.5 million upfront payment, for the exclusive license to develop and commercialize TU2670 within China. “We recently completed tech transfer of TU2970, which met the condition for the short-term milestone of $1.5 million that we expect to receive early next year,” an official at TiumBio said. “The Chinese drugmaker plans to apply for a clinical trial of TU2670 next year. With Hansoh Pharmaceutical’s extensive experience of clinical development and commercialization, it will be able to release the new drug early in China.” Separately, TiumBio is conducting a phase 2a trial of TU2670 in 80 patients in five countries in Europe. The official said the company achieved about 60 percent of the patient enrollment goal and the trial was progressing smoothly. “We are discussing additional licensing deals with multiple pharmaceutical firms in North America and Europe. Once we complete the phase 2a trial in Europe, the value of a licensing deal will go up,” he said. According to TiumBio, TU2670 is an oral GnRH (Gonadotropin-releasing hormone) antagonist. The company expects the investigational drug to suppress GnRH stably with less dose than AbbVie’s Orilissa (elagolix) and improve medication convenience (once daily). In 2019, TiumBio licensed out TU2670 to Daewon Pharmaceutical, and Daewon is conducting a local phase 2 study to treat uterine fibroids.

AbbVie Investments

3 Investments

AbbVie has made 3 investments. Their latest investment was in St. Jude Children's Research Hospital as part of their Grant on December 12, 2018.

CBI Logo

AbbVie Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/3/2018

Grant

St. Jude Children's Research Hospital

$50M

Yes

1

6/12/2017

Debt

Subscribe to see more

$99M

Subscribe to see more

10

5/14/2013

Project Finance

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/3/2018

6/12/2017

5/14/2013

Round

Grant

Debt

Project Finance

Company

St. Jude Children's Research Hospital

Subscribe to see more

Subscribe to see more

Amount

$50M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

AbbVie Portfolio Exits

1 Portfolio Exit

AbbVie has 1 portfolio exit. Their latest portfolio exit was Carisma Therapeutics on September 21, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/21/2022

Acq - Pending

$99M

1

Date

9/21/2022

Exit

Acq - Pending

Companies

Valuation

$99M

Acquirer

Sources

1

AbbVie Acquisitions

9 Acquisitions

AbbVie acquired 9 companies. Their latest acquisition was Syndesi Therapeutics on March 01, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/1/2022

Series A

$99M

$24.4M

Acquired

5

6/24/2021

Subscribe to see more

$99M

Subscribe to see more

10

3/2/2021

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

7/15/2019

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

5/25/2019

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/1/2022

6/24/2021

3/2/2021

7/15/2019

5/25/2019

Investment Stage

Series A

Series A

Series A

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$24.4M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

10

10

10

AbbVie Partners & Customers

10 Partners and customers

AbbVie has 10 strategic partners and customers. AbbVie recently partnered with iSTAR Medical on July 7, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

7/20/2022

Partner

Belgium

AbbVie, iSTAR enter alliance to support MINIject MIGS device

AbbVie and iSTAR Medical have entered into a strategic alliance to develop and commercialize the MINIject minimally invasive glaucoma surgical device for patients with glaucoma , according to a press release .

2

7/13/2022

Partner

United States

CytomX Therapeutics Provides Strategic Update

CX-2029 is part of CytomX Therapeutics , Inc. 's partnership with AbbVie .

1

7/8/2022

Partner

United States

AbbVie dumps an early-stage drug in $225M Alzheimer's alliance with Alector

Back in November , as Biogen and the controversy surrounding Aduhelm soaked up the attention around Alzheimer 's R&D , Alector quietly presented Phase I data for an AbbVie-partnered program at the annual conference for Clinical Trials on Alzheimer 's Disease .

2

7/8/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

6/22/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

7/20/2022

7/13/2022

7/8/2022

7/8/2022

6/22/2022

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

Belgium

United States

United States

United States

United States

News Snippet

AbbVie, iSTAR enter alliance to support MINIject MIGS device

AbbVie and iSTAR Medical have entered into a strategic alliance to develop and commercialize the MINIject minimally invasive glaucoma surgical device for patients with glaucoma , according to a press release .

CytomX Therapeutics Provides Strategic Update

CX-2029 is part of CytomX Therapeutics , Inc. 's partnership with AbbVie .

AbbVie dumps an early-stage drug in $225M Alzheimer's alliance with Alector

Back in November , as Biogen and the controversy surrounding Aduhelm soaked up the attention around Alzheimer 's R&D , Alector quietly presented Phase I data for an AbbVie-partnered program at the annual conference for Clinical Trials on Alzheimer 's Disease .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

2

10

10

AbbVie Service Providers

1 Service Provider

AbbVie has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

AbbVie Team

34 Team Members

AbbVie has 34 team members, including current Chief Executive Officer, Richard A. Gonzalez.

Name

Work History

Title

Status

Richard A. Gonzalez

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Richard A. Gonzalez

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

You May Also Like

Pfizer Logo
Pfizer

Pfizer (NYSE: PFE) offers a diversified health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer products. It works across various markets to promote wellness, prevention, treatments, and cures that challenge feared diseases. The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. The company was founded in 1849 and is based in New York, New York.

athenahealth Logo
athenahealth

athenahealth offers billing, practice management, and EHR services. athenahealth's offering is a web-based software, rules database offered as a subscription to physicians that combines in-office practice management functionality with a billing service. It is based in Watertown, Massachusetts.

Limbix Logo
Limbix

Limbix makes virtual reality and digital treatment tools for therapists.

A
Atentiv

Atentiv is committed to delivering the promise of new cognitive skills for millions of children around the world so that they can achieve success in school, at home and in life. By working as a team, in partnership with educators and clinicians, the company seeks to drive transformative change in education and many other areas of unmet educational and clinical need. The ATENTIVmynd Games is a product platform of personalized digital learning tools that uses an individual's unique 'cognitive signature' of brain wave activity to measure, train and manage multiple cognitive function development that significantly improve attention and impulse control.

Virta Health Logo
Virta Health

Virta Health develops a clinically-proven treatment to safely and sustainably reverse type 2 diabetes and other chronic metabolic diseases without the use of medications or surgery.

S
SYNAPS Dx

SYNAPS Dx focuses on the research, development, and commercialization of diagnostics for neurodegenerative disorders and conditions such as Alzheimer's Disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.